WO1998031354A3 - Use of 5-HT2b agonists or potentiators in CNS disorders - Google Patents

Use of 5-HT2b agonists or potentiators in CNS disorders Download PDF

Info

Publication number
WO1998031354A3
WO1998031354A3 PCT/EP1998/000380 EP9800380W WO9831354A3 WO 1998031354 A3 WO1998031354 A3 WO 1998031354A3 EP 9800380 W EP9800380 W EP 9800380W WO 9831354 A3 WO9831354 A3 WO 9831354A3
Authority
WO
WIPO (PCT)
Prior art keywords
potentiators
cns disorders
ht2b
agonists
ht2b agonists
Prior art date
Application number
PCT/EP1998/000380
Other languages
French (fr)
Other versions
WO1998031354A2 (en
Inventor
Guy Anthony Kennett
Original Assignee
Smithkline Beecham Plc
Guy Anthony Kennett
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc, Guy Anthony Kennett filed Critical Smithkline Beecham Plc
Publication of WO1998031354A2 publication Critical patent/WO1998031354A2/en
Publication of WO1998031354A3 publication Critical patent/WO1998031354A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin

Abstract

The present invention discloses the use of 5-HT2B agonists or positive allosteric modulators (enhancers) such as paroxetine or BW-723C86 in the treatment of various CNS, affective, behavioral, migraine or feeding disorders, and in particular in depression.
PCT/EP1998/000380 1997-01-17 1998-01-13 Use of 5-ht2b agonists or potentiators in cns disorders WO1998031354A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9700899.9 1997-01-17
GBGB9700899.9A GB9700899D0 (en) 1997-01-17 1997-01-17 Novel treatment

Publications (2)

Publication Number Publication Date
WO1998031354A2 WO1998031354A2 (en) 1998-07-23
WO1998031354A3 true WO1998031354A3 (en) 1998-09-17

Family

ID=10806125

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/000380 WO1998031354A2 (en) 1997-01-17 1998-01-13 Use of 5-ht2b agonists or potentiators in cns disorders

Country Status (2)

Country Link
GB (1) GB9700899D0 (en)
WO (1) WO1998031354A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000016761A2 (en) 1998-09-18 2000-03-30 Alcon Laboratories, Inc. Serotonergic 5ht2 agonists for treating glaucoma
US6956036B1 (en) 2000-03-17 2005-10-18 Alcon, Inc. 6-hydroxy-indazole derivatives for treating glaucoma
AU2001216035A1 (en) * 2000-03-17 2001-10-03 Alcon Universal Ltd. 5-hydroxy indole derivatives for treating glaucoma
US6806285B1 (en) 2000-03-17 2004-10-19 Alcon, Inc. 5-Hydroxyl indole derivatives for treating glaucoma
AU2001219185A1 (en) 2000-03-17 2001-10-03 Alcon, Inc. 2-acylaminobenzimidazole derivatives for treating glaucoma
US7005443B1 (en) 2000-03-17 2006-02-28 Alcon, Inc. 5-Hydroxy indazole derivatives for treating glaucoma
US7012090B1 (en) 2000-03-17 2006-03-14 Alcon, Inc. Pyranoindoles for treating glaucoma
EP1392658A4 (en) 2001-06-01 2004-10-13 Alcon Inc Novel fused indazoles and indoles and their use for the treatment of glaucoma
EP1392292B1 (en) 2001-06-01 2006-03-01 Alcon, Inc. Pyranoindazoles and their use for the treatment of glaucoma
WO2002098400A1 (en) 2001-06-01 2002-12-12 Alcon, Inc. Novel arylaminopropane analogues and their use for the treatment of glaucoma
TW593302B (en) 2001-12-20 2004-06-21 Alcon Inc Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
WO2004054572A2 (en) 2002-12-13 2004-07-01 Alcon, Inc. Novel benzopyran analogs and their use for the treatment of glaucoma
AU2004283196B2 (en) 2003-09-17 2011-08-25 Janssen Pharmaceutica, N.V. Fused heterocyclic compounds
WO2005053688A1 (en) 2003-11-26 2005-06-16 Alcon, Inc. Substituted furo[2,3-g] indazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
US7129257B1 (en) 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
TW200520760A (en) 2003-12-15 2005-07-01 Alcon Inc Substituted [1,4] oxazino [2,3-g] indazoles for the treatment of glaucoma
US7425572B2 (en) 2004-12-08 2008-09-16 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994025012A2 (en) * 1993-04-28 1994-11-10 Smithkline Beecham Plc Medicaments for treatment of migraine, epilepsy and feeding disorders
WO1996029074A1 (en) * 1995-03-22 1996-09-26 Eli Lilly And Company Methods of treating or preventing pain or nociception

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994025012A2 (en) * 1993-04-28 1994-11-10 Smithkline Beecham Plc Medicaments for treatment of migraine, epilepsy and feeding disorders
WO1996029074A1 (en) * 1995-03-22 1996-09-26 Eli Lilly And Company Methods of treating or preventing pain or nociception

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AINSWORTH K ET AL: "Is #BW# #723C86#-induced hyperphagia an in vivo model of rat central 5-HT-2B receptor function?", BRITISH JOURNAL OF PHARMACOLOGY, 117 (PROC. SUPPL.). 1996. 178P., XP002069367 *
DUXON ET AL.: "Activation of 5HT-2B receptors in the medial amygdala causes anxiolysis in the social interaction test in the rat", NEUROPHARMACOLOGY, vol. 36, no. 4-5, April 1997 (1997-04-01) - May 1997 (1997-05-01), pages 601 - 608, XP002069368 *
KENNETT ET AL: "Effects o the 5-HT2B receptor agonist, BW 723C86, on three rat models of anxiety", BR. J. PHARMACOL., vol. 117, no. 7, April 1996 (1996-04-01), pages 1443 - 1448, XP002069364 *
KENNETT G A ET AL: "Does chronic administration of paroxetine or the 5-HT-2B receptor agonist, #BW# #723C86#, affect rat 5-HT-2B receptor function?", SOCIETY FOR NEUROSCIENCE ABSTRACTS, 22 (1-3). 1996. 1778., XP002069366 *
KENNETT GA ET AL: "Effect of chronic administration of selective 5-hydroxytryptamine and noradrenaline uptake inhibitors on a putative index of 5-HT2C/#2B# #receptor# function.", NEUROPHARMACOLOGY, DEC 1994, 33 (12) P1581-8, ENGLAND, XP002069365 *

Also Published As

Publication number Publication date
WO1998031354A2 (en) 1998-07-23
GB9700899D0 (en) 1997-03-05

Similar Documents

Publication Publication Date Title
WO1998031354A3 (en) Use of 5-HT2b agonists or potentiators in CNS disorders
IL158867A0 (en) Ostepontin and agonists thereof in treatment and/or prevention of neurological diseases
EP1040827A3 (en) Use of 2-alkylpyrrolidines for the treatment of diabetes
WO2001079460A3 (en) Polypeptides having haloperoxidase activity
AU2002343557A1 (en) Substituted aryl 1,4-pyrazine derivatives
WO2004047838A3 (en) Pharmaceutical composition comprising beta-3-adrenoceptor agonists and antimuscarinic agents
AU2002339691A1 (en) Agonists and antagonists of prolixin for the treatment of metabolic disorders
ZA989667B (en) The use of MMP-13 selective inhibitors for the treatment of osteoarthritis and other MMP-mediated disorders.
CA2257010A1 (en) Methods and compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia
ZA979961B (en) 5-HT1F agonists
AU1753699A (en) Application of vasopressin antagonists for treating disturbances or illnesses ofthe inner ear
YU13301A (en) Muscarinic agonists and antagonists
EP1724283A3 (en) Corticotropin releasing factor receptor 2 agonists
WO2002039997A3 (en) Ace-2 modulating compounds and use thereof
WO2001015677A3 (en) Use of 5-ht1b/1d agonists to treat otic pain
WO2000040232A3 (en) Bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
AU2003215190A8 (en) Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules.
AU3630297A (en) Galanin
WO2004037168A3 (en) Treatment of pancreatitis with amylin
WO2002003684A3 (en) Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist
WO2000042201A3 (en) Human peptidases
PL340459A1 (en) Agonists of 5ht1f
AU3896899A (en) Compositions for the treatment of tumors, and uses thereof
WO2004112729A8 (en) Dual function compounds and uses thereof
WO2003059332A3 (en) Use of an anti-microtubule agent for the treatment of uveitis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998533697

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase